ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Open Access
- 23 June 2025
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 206, 108635
Abstract
No abstract availableFunding Information
- AstraZeneca HealthCare Foundation
- AstraZeneca (ESR-23-22211)
This publication has 10 references indexed in Scilit:
- Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.Journal of Clinical Oncology, 2025
- Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trialThe Lancet Respiratory Medicine, 2024
- Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2024
- Perioperative Nivolumab in Resectable Lung CancerNew England Journal of Medicine, 2024
- Neoadjuvant Chemoimmunotherapy for NSCLCJAMA Oncology, 2024
- Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung CancerJAMA, 2024
- Perioperative Durvalumab for Resectable Non–Small-Cell Lung CancerNew England Journal of Medicine, 2023
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung CancerNew England Journal of Medicine, 2023
- Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialThe Lancet Oncology, 2022
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialThe Lancet, 2021